Inverness Bids Against Beckman Coulter for Biosite

Barnes & Noble to take immaterial charges related to stock option accounting; plus more stocks in the news Thursday

Biosite (BSTE) gets a letter from Inverness Medical Innovations (IMA) that says Inverness prepared to offer to acquire all of Biosite, other than the 4.9% it already owns, for $90 per share cash. On Mar. 25, Biosite received an $85 per share offer from Beckman Coulter (BEC).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.